AstraZeneca’s chief executive has hailed the “vital importance of the US” to the British drugmaker, days after announcing a $50bn (£37bn) investment in the country at a time when Donald Trump’s threatened tariffs are looming over the sector.
Pascal Soriot, who leads Britain’s most valuable company, refused to comment, however, on recent media reports that AstraZeneca is considering moving its main stock market listing from the UK to the US.
